🔴 ABIVAX is trading 5.82% down today after disappointing Ionis Pharmaceuticals trial results

ABIVAX is trading 5.82% down now at €93.85 after disappointing Ionis Pharmaceuticals trial results weakened sentiment across biotechnology.

• The decline is consistent with the reported Paris-listed move and 126,106-share volume on September 15, 2026.
• Broader pressure included biotech-sector weakness, analyst downgrades, reduced M&A optimism, and cautious risk sentiment.
• No new ABIVAX-specific announcement was identified for September 16, 2026; the available company calendar lists H1 2026 results for September 21.